The Morita-Baylis-Hillman adducts of β-aryl nitroethylenes with other activated alkenes: synthesis and anticancer activity studies†‡

Mamta Dadwal, Renu Mohan, Dulal Panda, Shaikh M. Mobin and Irishi N. N. Namboothiri*

Received (in Cambridge, UK) 30th August 2005, Accepted 18th October 2005 First published as an Advance Article on the web 21st November 2005

DOI: 10.1039/b512267h

The Morita-Baylis-Hillman (MBH) adducts of β-aryl nitroethylenes with methyl vinyl ketone (MVK) and acrylate, formed in moderate to good yield when mediated by imidazole/ LiCl in THF at room temperature, inhibit HeLa cell proliferation by binding to tubulin.

The coupling of the α-position of activated alkenes with various carbon electrophiles mediated by a tertiary amine or tertiary phosphine, popularly known as the Morita-Baylis-Hillman (MBH) reaction, has emerged as an important C-C bond forming reaction in organic synthesis. 1,2 It provides a simple, convenient and atom-economical methodology for the synthesis of useful multifunctional molecules.² Although various activated alkenes have been employed in the MBH reaction,² conjugated nitroalkenes³ have not found a place in more than three decades of the MBH chemistry. 4-7 However, the superior Michael acceptor ability of conjugated nitroalkenes³ together with the wellrecognized status of the nitro group as a synthetic chameleon⁸ call for greater attention on nitroalkenes as substrates for the MBH reaction.

The ability of nitroalkenes to exhibit important biological properties and function as key substrates and/or intermediates in the synthesis of many potent drugs and bioactive natural products makes them attractive molecules in the biological domain as well.⁹ Among various biological properties, the anticancer properties of nitroalkenes have been scarcely investigated. 10,11

In this report, we describe our results on the successful MBH type reaction of β-aryl nitroethylenes with other activated alkenes such as methyl vinyl ketone (MVK) and acrylate and the preliminary evaluation of the novel MBH adducts in their ability to inhibit human cervical cancer (HeLa) cell proliferation by binding to tubulin.

There is a handful of reports in the literature where activated alkenes underwent self-condensation (dimerization) in the absence of another electrophile. 12,13 These include DABCO catalyzed

dimerization of alkyl vinyl ketone and acrylonitrile,12 and TDAP (tris-dimethylaminophosphine) or DABCO catalyzed dimerization of acrylate. 13 However, to our knowledge, there are only two reports where activated alkenes have been consciously used as electrophiles in the MBH reaction.¹⁴

At first, the reaction of our model substrate 2-nitrovinyl furan (NVF) 1a with MVK 2 was carried out in the presence of 10 mol% of various catalysts such as imidazole, 15 DMAP, 16 DABCO, DBU and various other catalysts under a variety of conditions (see supplementary information[‡]).² However, while imidazole and DMAP provided isolable amounts of the desired MBH adduct, all others failed to catalyze the reaction. Subsequently, the amount of imidazole required to obtain the best yields of the MBH adduct was confirmed to be 100 mol%.

Having optimized the amount of imidazole, the co-catalytic activity of a variety of additives which are capable of (a) forming imine/iminium of the enone; (b) activating the enone via hydrogen bonding; and/or (c) inhibiting polymerization of the substrate (nitroalkene), was investigated (see supplementary information‡). But, any appreciable improvement in the yield could be achieved only when hydroquinone and p-methoxyphenol were used in conjunction with imidazole in the reaction between NVF 1a and MVK 2. However, further attempts to improve the yields in these imidazole mediated reactions using hydroquinone as the additive and employing the optimized conditions for the reaction of other nitroalkenes 1b-e with MVK 2 led to unsatisfactory results (Table 1). This prompted us to examine the effect of salt¹⁷ on our MBH reaction by employing LiCl as the additive. 18

Table 1 The MBH reaction of β-aryl nitroethylenes 1 with MVK 2 in the presence of 100 mol% imidazole, and 10 mol% hydroquinone in THF/H_2O (1:1) at room temperature

Entry	1, 3	Ar	Time (min)	Isolated yield (%) of 3 ^a
1	a	2-Furyl	60	39
2	b	2-Thienyl	60	41
3	c	4-ClPh	120	22
4	d	4-OMePh	60	16
5	e	Ph	5	Polymerization

^a Complete consumption of 1 was observed in all the cases.

Fax: +91-22-2576-7152; Tel: + 91-22-2576-7196

E-mail: panda@btc.iitb.ac.in; Fax: +91-22-2572-3480;

Tel: + 91-22-2576-7838

^aDepartment of Chemistry, Indian Institute of Technology, Bombay, Mumbai 400 076, India. E-mail: irishi@iitb.ac.in;

^bSchool of Biosciences and Bioengineering, Indian Institute of Technology, Bombay, Mumbai 400 076, India.

^cNational Single Crystal X-ray Diffraction Facility, Indian Institute of Technology, Bombay, Mumbai 400 076, India

[†] Dedicated to the memory of the late Professor A. K. Lala.

[‡] Electronic supplementary information (ESI) available: X-ray data for 3g in CIF format, experimental procedures, full characterization data, copies of 1H and 13C NMR spectra and HPLC profiles for all the new compounds. See DOI: 10.1039/b512267h

Although the imidazole mediated reaction of NVF 1a with MVK 2 in the presence of LiCl in THF/H₂O (1:1) was complete in 1 h, it provided only low yield (22%) of the MBH product 3a. Subsequently, exclusion of water from the reaction mixture led to isolation of the desired product 3a in satisfactory yield (44%). Other polar aprotic solvents such as DMF, acetonitrile and dioxane provided 3a only in much lower yields.

The imidazole-LiCl ratio of 100 mol%/0.5 M was found to be optimum because increasing the amount of imidazole to 200 mol% or LiCl to 1, 2 and 3 M did not have any appreciable influence on the yield. On the other hand, decreasing the amount of imidazole to 50 mol% led to dramatic decrease in the yield (18%). Finally, the optimum ratio of the MBH substrate 1a and the electrophile 2 was found to be 1:3. While decreasing the amount of MVK 2 led to decrease in the yield, increasing the ratio from 1:3 to 1:4 or 1:5 did not affect the yield at all.

In view of the fact that stoichiometric amounts of imidazole in conjunction with 0.5 M LiCl in THF emerged as the best system for the MBH reaction of NVF 1a with MVK 2, the scope of the reaction was extended by reacting a variety of aromatic and heteroaromatic nitroalkenes 1b-j with MVK 2 (Table 2, Entries 2–10). Although the chemical yields were moderate in these cases (28–60%), clean, isomerically pure products 3a–j were isolated after column chromatography.

Having established the experimental conditions for the reaction between nitroalkenes 1 and MVK 2, we explored the reactivity of other activated alkenes as electrophiles under these conditions. Thus, selected nitroalkenes 1a and 1g-i were reacted with ethyl acrylate 4 which afforded the desired MBH products 5a and 5g-i, respectively, though, in low yield (Table 3, Entries 1-4). All our attempts to use other activated alkenes such as acrolein, acrylonitrile, acrylamide and nitroethylene as terminal electrophiles have not been successful.

The geometry of the double bond in products 3 and 5 was confirmed to be E by performing 2D-NOESY experiment on a representative compound 3g. One of the CH₂ groups and the CH₃ group in 3g have strong NOEs with the Ar protons, but only weak

Table 2 The MBH reaction of β-aryl nitroethylenes 1 with MVK 2 in the presence of 100 mol% imidazole, and 0.5 M LiCl in THF at room temperature

48

56

47

60

28

Table 3 The MBH reaction of β-aryl nitroethylenes 1 with ethyl acrylate 4 in the presence of 100 mol% imidazole, and 0.5 M LiCl in THF at room temperature

Ar	+ NO ₂		CO ₂ Et nidazole (100 mol %) CI (0.5 M), THF, RT		
1		4	5		
Entry	1, 5	Time (h	Isolated yield (%) of 5 ^a		
1	a	56	21		
2	g	34	18		
3	h	88	21		
4	i	90	24		
^a 5–12% of 1 was recovered.					

NOEs with the benzylic olefinic proton. In fact, all the reactions provided isomerically pure MBH adducts and there was no evidence for the formation of the other geometrical isomer. The structure was further unambiguously established by single crystal X-ray analysis of **3g** (see also supplementary information.¹⁹). ¹⁹

The effect of the MBH adducts on human cervical cancer (HeLa) cells were examined by incubating HeLa cells with 5 µM and 25 μM of the MBH adducts 3a-j, 5a and 5g-i for 24 hours.²⁰ While most of the MBH adducts produced 70-100% inhibition of HeLa cell proliferation at 25 μM concentrations, three of the MBH adducts, viz. 3e, 3f and 3g were found to produce more than 70% inhibition even at 5 μM concentration.‡ MBH adduct 3f was found to be the most potent inhibitor of HeLa cell proliferation among the tested compounds producing 80% inhibition at 5 μM.

To determine the binding affinity of MBH adducts 3a-j, 5a and **5g-i** to tubulin, tubulin (1 μ M) was incubated with 10 μ M each of all the 14 MBH adducts for 30 min at room temperature.²¹ In all the cases, a decrease in the intrinsic tryptophan fluorescence of tubulin was observed which confirmed that all the compounds were binding to tubulin.‡

In conclusion, activated alkenes such as MVK and acrylate reacted as electrophiles in the MBH reaction of a variety of aromatic and heteroaromatic nitroalkenes and provided novel α-substituted nitroalkenes. Normally, β-substituted activated alkenes do not react or react only sluggishly in the MBH type reactions. However, in the case of nitroalkenes, β-substituted ones were found to react satisfactorily. One of the MBH adducts was found to be a potent inhibitor of HeLa cell proliferation at 5 μM concentrations by binding to tubulin. Applications of these MBH adducts for the synthesis of novel 1,4-dicarbonyl compounds, 1,4amino alcohols, γ -amino acids *etc* will be reported in due course.

We thank CSIR and DBT, India, for financial assistance, SAIF, IIT Bombay, for NMR data, Dr Rachel Persky, Bar-Ilan University, Israel, for the HRMS data for some of the compounds and Mr Madhu Ganesh, Department of Chemistry, IIT Bombay, for the HPLC profiles.

Notes and references

1 (a) K. Morita, Z. Suzuki and H. Hirose, Bull. Chem. Soc. Jpn., 1968, 41, 2815; (b) A. B. Baylis and M. E. D. Hillman, Ger. Offen., 1972, DE 2155113; (A. B. Baylis and M. E. D. Hillman), Chem. Abs., 1972, 77,

3,4-(OCH2O)Ph

3,4-(OMe)₂Ph

4-CF₃Ph

a 15-23% of 1 was recovered.

g

h

i

i

8

10

- 434174; M. E. D. Hillman and A. B. Baylis, *U. S. Patent*, 1973, US 3743669.
- 2 For recent reviews: (a) D. Basavaiah, A. J. Rao and T. Satyanarayana, Chem. Rev., 2003, 103, 811; (b) T. Kataoka and H. Kinoshita, Eur. J. Org. Chem., 2005, 45.
- 3 For a recent review: O. M. Berner, L. Tedeschi and D. Enders, Eur. J. Org. Chem., 2002, 1877.
- 4 Baylis and Hillman in their original patent (Ref. 1b) have reported the reaction between nitroethylene and acetaldehyde in the presence of DABCO. However, no details or further reports on this or similar reactions are available.
- 5 For α-hydroxymethylation of nitroalkenes via the MBH reaction, see: N. Rastogi, I. N. N. Namboothiri and M. Cojocaru, *Tetrahedron Lett.*, 2004. 45, 4745.
- 6 For reaction between aliphatic nitroalkenes and ethyl-2-bromomethyl-acrylate under the DBU catalyzed conditions: R. Ballini, L. Barboni, G. Bosica, D. Fiorini, E. Mignini, A. Palmieri, *Tetrahedron*, 2004, 60, 4995. This reaction apparently involves an overall allylic displacement of bromide and the product is not a conjugated nitroalkene.
- 7 The reluctance of the nitroalkenes, despite being powerful Michael acceptors, is attributable to the reversibility of the first step of the MBH reaction, i.e. Michael type addition of the tertiary amine or the phosphine catalyst to nitroalkene, poor nucleophilicity of the nitronate and/or the propensity of the nitroalkene to undergo polymerization.
- 8 For a recent review on nitro compounds: R. Ballini and M. Petrini, *Tetrahedron*, 2004, **60**, 1017.
- 9 For selected articles: (a) G. W. Kabalka and R. S. Varma, Org. Prep. Proc. Int., 1987, 19, 283 and the references cited therein; (b) K. Blades, A. H. Butt, G. S. Cockerill, H. J. Easterfield, T. P. Lequeux and J. M. Percy, J. Chem. Soc., Perkin Trans. 1, 1999, 3609; (c) Y. Hoashi, T. Yabuta and Y. Takemoto, Tetrahedron Lett., 2004, 45, 9185.
- 10 For the antitumor activity of nitroalkene against P-388 murine lymphocytic leukemia: (a) B. K. Cassels, S. Herreros, C. Ibanez, M. C. Rezende, C. Sebastian and S. Sepulveda, An. Asoc. Quim. Argent., 1982, 70, 283, Chem. Abs., 1982, 97, 400402; (b) K. -Y. Zee-Cheng and C. -C. Cheng, J. Med. Chem., 1969, 12, 157.

- 11 For the evaluation of nitroalkenes and their α-hydroxymethylated derivatives (MBH adducts with formaldehyde) for their anticancer activity by targeting microtubules/tubulins: R. Mohan, N. Rastogi, I. N. N. Namboothiri, S. M. Mobin and D. Panda, unpublished results.
- (a) D. Basavaiah, V. V. L. Gowriswari and T. K. Bharathi, *Tetrahedron Lett.*, 1987, 28, 4591;
 (b) D. Basavaiah, V. V. L. Gowriswari, P. Dharma Rao and T. K. Bharathi, *J. Chem. Res.* (S), 1995, 267.
- (a) H. Amri, M. Rambaud and J. Villieras, *Tetrahedron Lett.*, 1989, 30, 7381;
 (b) S. E. Drewes, N. D. Emslie and N. Karodia, *Synth. Commun.*, 1990, 20, 1915.
- 14 (a) T. Kitazume, K. Tamura, Z. Jiang, N. Miake and I. Kawasaki, J. Fluor. Chem., 2002, 115, 49; (b) J. R. Hwu, G. H. Hakimelahi and C. -T. Chou, Tetrahedron Lett., 1992, 33, 6469.
- 15 For a recent imidazole catalyzed MBH reaction: S. Luo, P. G. Wang and J.- P. Cheng, *J. Org. Chem.*, 2004, **69**, 555.
- 16 For a recent DMAP catalyzed MBH reaction: R. Octavio, M. A. de Souza and M. L. A. A. Vasconcellos, Synth. Commun., 2003, 33, 1383.
- 17 (a) V. K. Aggarwal, D. K. Dean, A. Mereu and R. Williams, J. Org. Chem., 2002, 67, 510; (b) A. Kumar and S. S. Pawar, Tetrahedron, 2003, 59, 5019.
- 18 (a) Recent studies have shown that LiCl catalyzes the MBH reaction by functioning as a salting out agent: see Ref. 17b; (b) The authors thank one of the referees for pointing out the analogy of the imidazole/LiCl catalyst system with the triethylamine/LiCl combination in the Masamune–Roush variant of the Horner–Wadsworth–Emmons reaction.
- 19 Selected X-ray crystallographic data for **3g**. $C_{12}H_{13}NO_3$, M=219.23, triclinic P1, a=7.2530(10), b=7.9810(7), c=10.7050(9), $\alpha=106.198(7)$, $\beta=104.883(9)$, $\gamma=97.193(9)$, V=562.02 (10) Å³, Z=2, $D_{\rm calc}=1.295$ g cm⁻³, $\mu=0.094$ mm⁻¹, 2153 reflections measured, $R_1=0.0453$, $R_{\rm w}=0.1010$. CCDC 283074. For crystallographic data in CIF or other electronic format see DOI: 10.1039/b512267h.
- 20 For a recent study on the inhibition of HeLa cell proliferation: K. Gupta, J. Bishop, A. Peck, J. Brown, L. Wilson and D. Panda, *Biochemistry*, 2004. 43, 6645.
- 21 For a recent tubulin binding study: K. Gupta and D. Panda, *Biochemistry*, 2002, **41**, 13029.